Author

M. Ehnert

Observed names: Michael Ehnert, michael Ehnert

Institution: Eli Lilly (United States)

Observed institutions: Eli Lilly (United States), Asklepios Klinik St. Georg

OpenAlex ID: A5023966170

Reno, a European postmarket surveillance registry, confirms effectiveness of coronary brachytherapy in routine clinical practice

2003 · V. Coen, P. Serruys, et al. · International Journal of Radiation Oncology*Biology*Physics · 44

Is the time interval between surgery and radiotherapy important in operable nonsmall cell lung cancer? A retrospective analysis of 340 cases

1997 · Florian Würschmidt, Henry Bünemann, et al. · International Journal of Radiation Oncology*Biology*Physics · 25

Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro

2006 · U. Eismann, O. Oberschmidt, et al. · Journal of Clinical Oncology · 9

Pemetrexed: Target gene expression in human solid tumors correlates with chemosensitivity patterns

2004 · O. Oberschmidt, U. H. Eismann, et al. · Journal of Clinical Oncology · 1

487 Correlations of in vitro chemosensitivity of solid tumors to Pemetrexed (P, ALIMTA®) and target gene expression

2004 · O. Oberschmidt, U. Eismann, et al. · European Journal of Cancer Supplements

RENO: a European surveillance registry of coronary brachytherapy with the Novoste™ Beta-Cath™ System

2001 · V. Coen, W. Sauerwein, et al. · International Journal of Radiation Oncology*Biology*Physics

33 RENO: A European surveillance registry of coronary brachytherapy with the NovosteTM Beta-CathTM System

2001 · V. Coen, W. Sauerwein, et al. · Radiotherapy and Oncology

Possible negative impact on survival of too short an interval between surgery and postoperative radiotherapy in NSCLC

1997 · Florian Würschmidt, Henry Bünemann, et al. · European Journal of Cancer

Works count: 8

Citation count: 79

H-index: 3

I10-index: 2